Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review
We report a patient who has achieved complete remission and good tolerance with sintilimab plus bevacizumab and platinum-based chemotherapy after postoperative recurrence. The patient had KRAS mutation and MSS-type colon cancer, and his PD-1+CD8+ and CD3−CD19−CD14+CD16−HLA-DR were both positive. He has achieved a progression-free survival of 43 months and is still being followed up at our center. The above results suggest that this therapeutic regimen is a promising treatment modality for the management of pretreated, MSS-type and KRAS-mutated metastatic colorectal cancer although its application to the general publi...
Source: Frontiers in Immunology - March 28, 2024 Category: Allergy & Immunology Source Type: research
Cancers, Vol. 16, Pages 1328: Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma
In conclusion, TCM proportion at baseline might be a good indicator of the efficacy of Atez/Bev therapy. Furthermore, observation of increasing TEM proportions might be an early predictor of the potential clinical benefits of treatment. (Source: Cancers)
Source: Cancers - March 28, 2024 Category: Cancer & Oncology Authors: Yuki Shirane Yasutoshi Fujii Atsushi Ono Hikaru Nakahara Clair Nelson Hayes Ryoichi Miura Serami Murakami Naoya Sakamoto Shinsuke Uchikawa Hatsue Fujino Takashi Nakahara Eisuke Murakami Masami Yamauchi Daiki Miki Tomokazu Kawaoka Koji Arihiro Masataka Tsu Tags: Article Source Type: research
HER2-Positive Metastatic Colorectal Cancer
Opinion statementTargeted treatment strategies are available for human epidermal growth factor receptor 2 (HER2) –positive (amplified and/or overexpressed) metastatic colorectal cancer (mCRC), and HER2 testing is indicated in patients with mCRC. At present, standard of care first-line treatment for those with HER2-positive mCRC remains chemotherapy in combination with epidermal growth factor receptor (EGFR) inhibitors or bevacizumab, depending onRAS/BRAF mutational status and tumor sidedness. HER2-targeted agents should be considered for those withRAS/BRAF wild-type disease in subsequent-line treatment and in first-line ...
Source: Current Treatment Options in Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma
The objective response rate of the combination-therapy group (80.0%) was higher than that of the atezo/bev alone group (21.1%; p = 0.005). Progression-free survival (PFS) and overall survival (OS) were longer in the combination group (medians for PFS and OS not reached) than in the atezo/bev alone group (median PFS, 7.4 months; median OS, 19.8 months) (PFS, p = 0.004; OS, p < 0.001). The albumin-bilirubin score did not change, and no severe complications occurred after locoregional treatment. When performed in a minimally invasive manner, on-demand selective locoregional treatment combined with first-line atezo/bev coul...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Tasuku Nakabori Sena Higashi Yutaro Abe Kaori Mukai Toshiki Ikawa Koji Konishi Noboru Maeda Katsuyuki Nakanishi Shinichiro Hasegawa Hiroshi Wada Kazuyoshi Ohkawa Source Type: research
Bilateral Retinal Venous Occlusion in Atypical Hemolytic-Uremic Syndrome Due to Complement Factor H Mutation
CONCLUSION: Diagnosis of aHUS is challenging especially during pregnancy and the postpartum period. Although ocular involvement is quite rare, we described bilateral RVO in aHUS case with homozygous nonsense mutation (c.2134 G > T p.G712). Dexamethasone implant should be considered for the treatment of RVO in aHUS cases.PMID:38536978 | DOI:10.1080/09273948.2024.2333401 (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - March 27, 2024 Category: Allergy & Immunology Authors: Saban Gonul Serhat Eker Source Type: research
Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma
The objective response rate of the combination-therapy group (80.0%) was higher than that of the atezo/bev alone group (21.1%; p = 0.005). Progression-free survival (PFS) and overall survival (OS) were longer in the combination group (medians for PFS and OS not reached) than in the atezo/bev alone group (median PFS, 7.4 months; median OS, 19.8 months) (PFS, p = 0.004; OS, p < 0.001). The albumin-bilirubin score did not change, and no severe complications occurred after locoregional treatment. When performed in a minimally invasive manner, on-demand selective locoregional treatment combined with first-line atezo/bev coul...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Tasuku Nakabori Sena Higashi Yutaro Abe Kaori Mukai Toshiki Ikawa Koji Konishi Noboru Maeda Katsuyuki Nakanishi Shinichiro Hasegawa Hiroshi Wada Kazuyoshi Ohkawa Source Type: research
